Michael Metzger Sells 17,159 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Michael Metzger sold 17,159 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $360,853.77. Following the transaction, the chief executive officer directly owned 491,690 shares in the company, valued at approximately $10,340,240.70. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Syndax Pharmaceuticals Stock Up 2.6%

NASDAQ:SNDX traded up $0.56 during mid-day trading on Tuesday, hitting $21.75. 194,044 shares of the company’s stock traded hands, compared to its average volume of 1,262,057. Syndax Pharmaceuticals, Inc. has a twelve month low of $8.58 and a twelve month high of $22.73. The company has a debt-to-equity ratio of 2.78, a quick ratio of 4.42 and a current ratio of 4.64. The company has a market capitalization of $1.89 billion, a P/E ratio of -6.02 and a beta of 0.46. The company has a fifty day moving average of $20.72 and a 200 day moving average of $17.14.

Institutional Trading of Syndax Pharmaceuticals

Several institutional investors have recently bought and sold shares of SNDX. Larson Financial Group LLC increased its holdings in shares of Syndax Pharmaceuticals by 192.2% during the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after buying an additional 1,922 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Syndax Pharmaceuticals in the third quarter valued at about $53,000. Lazard Asset Management LLC acquired a new position in Syndax Pharmaceuticals during the 2nd quarter worth about $66,000. Tower Research Capital LLC TRC increased its position in Syndax Pharmaceuticals by 103.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after acquiring an additional 4,308 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Syndax Pharmaceuticals by 26.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after purchasing an additional 893 shares in the last quarter.

Analysts Set New Price Targets

SNDX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lowered their price target on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Wall Street Zen upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Syndax Pharmaceuticals in a report on Monday, October 27th. Finally, BTIG Research reissued a “buy” rating and set a $56.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $37.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.